KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $1.78.

  • Eli Lilly's Debt to Equity fell 1798.71% to $1.78 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.78, marking a year-over-year decrease of 1798.71%. This contributed to the annual value of $2.36 for FY2024, which is 152.64% up from last year.
  • Per Eli Lilly's latest filing, its Debt to Equity stood at $1.78 for Q3 2025, which was down 1798.71% from $2.17 recorded in Q2 2025.
  • Eli Lilly's 5-year Debt to Equity high stood at $2.48 for Q2 2021, and its period low was $1.51 during Q4 2022.
  • Moreover, its 5-year median value for Debt to Equity was $2.03 (2024), whereas its average is $2.0.
  • Its Debt to Equity has fluctuated over the past 5 years, first crashed by 5764.57% in 2021, then surged by 5407.9% in 2023.
  • Eli Lilly's Debt to Equity (Quarter) stood at $1.84 in 2021, then decreased by 18.29% to $1.51 in 2022, then soared by 54.08% to $2.32 in 2023, then increased by 1.53% to $2.36 in 2024, then dropped by 24.4% to $1.78 in 2025.
  • Its Debt to Equity stands at $1.78 for Q3 2025, versus $2.17 for Q2 2025 and $2.43 for Q1 2025.